

Chemicals | Q4FY23 Result Update

- Deepak Nitrite Q4FY23 numbers were broadly in line with our estimates. Sales grew by 4.8% YoY to Rs 19.6bn (D.est : Rs 20.4bn) (down 1.5% sequentially).
- EBITDA de-grew by 15.2% YoY to Rs 3.5bn (up 10.6% QoQ) (D.est : Rs 3.6bn) impacted by higher Opex cost (up 22.4% YoY).
- PAT saw a de-growth of 12.5% YoY (up 11.9% QoQ) to Rs 2.3bn (D.est : Rs 2.4bn).

Healthy outlook for Phenolics Business over FY24/FY25

Phenolic business registered a healthy performance in Q4FY23 with growth of 39.4% QoQ in revenues while EBIT margins also saw an uptick of ~440bps sequentially. Plants operated at high utilisation levels throughout the year with the Phenol plant clocking in an average rate of ~120% over FY23. This momentum is expected to continue over FY24 on the back of robust domestic demand. With further debottlenecking of its Phenol plant which is expected to increase the capacity by ~50% and addition of new downstream products the growth prospects remain healthy.

Capex of ~Rs 25bn over FY23-FY25 to drive future growth

DN has set out an extensive capex plan of ~Rs25bn which will be a mix of growth projects plus backward intergration activities. Its large scale investment plan will help it to broaden its product offerings with addition of new value-added downstreams, forward integration projects and new chemistry platforms and shall drive its future growth.

Outlook and Valuation

Timely execution of its capex projects and their speedy ramp up will remain a key to its growth in the near to medium term. We believe that entry into value added downstream derivatives, advanced chemistries and forward integration into Polycarbonates will help the company to subside the cyclicity in its business. We however remain cautious of the near term recessionary trends and thus have downward revised our estimates marginally. We have downgraded our rating to Accumulate with a revised target price of Rs 2,266 (22x FY25E EPS).

Q4FY23 Result (Rs Mn)

Particulars	Q4FY23	Q4FY22	YoY (%)	Q3FY23	QoQ (%)
Revenue	19,614	18,724	4.8	19,911	(1.5)
Total Expense	16,134	14,620	10.4	16,765	(3.8)
EBITDA	3,480	4,103	(15.2)	3,146	10.6
Depreciation	409	446	(8.3)	411	(0.4)
EBIT	3,070	3,657	(16.0)	2,735	12.3
Other Income	126	35	255.1	134	(5.9)
Interest	45	71	(36.8)	58	(23.5)
EBT	3,152	3,622	(13.0)	2,810	12.1
Tax	813	950	(14.4)	720	12.9
RPAT	2,339	2,672	(12.5)	2,091	11.9
APAT	2,339	2,672	(12.5)	2,091	11.9
			(bps)		(bps)
Gross Margin (%)	34.8	38.2	(338)	32.8	206
EBITDA Margin (%)	17.7	21.9	(417)	15.8	194
NPM (%)	11.9	14.3	(235)	10.5	142
Tax Rate (%)	25.8	26.2	(43)	25.6	18
EBIT Margin (%)	15.7	19.5	(388)	13.7	192

CMP	Rs 1,934		
Target / Upside	Rs 2,266 / 17%		
NIFTY	18,315		
Scrip Details			
Equity / FV	Rs 273mn / Rs 2		
Market Cap	Rs 264bn		
	USD 3.2bn		
52-week High/Low	Rs 2,357 / 1,681		
Avg. Volume (no)	319,078		
Bloom Code	DN IN		
Price Performance			
1M	3M	12M	
Absolute (%)	3	10	(3)
Rel to NIFTY (%)	1	7	(20)

Shareholding Pattern

	Sep'22	Dec'22	Mar'23
Promoters	45.7	49.1	4913.0
MF/Banks/FIs	10.0	15.1	1506.0
FIs	8.8	7.7	772.0
Public / Others	35.5	28.1	2809.0

Valuation (x)

	FY23P	FY24E	FY25E
P/E	31.0	23.2	18.8
EV/EBITDA	20.5	15.7	12.5
ROE (%)	22.9	24.7	24.4
RoACE (%)	21.6	23.6	23.5

Estimates (Rs bn)

	FY23P	FY24E	FY25E
Revenue	79.7	88.6	102.3
EBITDA	12.9	16.8	21.0
PAT	8.5	11.4	14.0
EPS (Rs.)	62.5	83.4	103.0

Analyst: Tejas Sonawane

Tel: +91 22 40969792

E-mail: tejass@dolatcapital.com

Associate: Alpesh Lad

Tel: +91 22 40969754

E-mail: alpeshl@dolatcapital.com

Segmental Performance

- Advanced Intermediates business registered a growth of 6.7% YoY to Rs 8bn. EBIT was down by 29.2% YoY to Rs 1.4bn registering an EBIT margin contraction of 865bps YoY to 17.1%.
- Phenolics business grew by 3.7% YoY to Rs 11.7bn. EBIT was flat at Rs 1.8bn translating into EBIT margin contraction of 45 bps YoY to 15.1%.

Exhibit 1: Actual vs Estimated

Particulars (Rs Mn)	Actual	Estimated	Variance (%)	Comments
Revenue	19,614	20,431	(4.0)	
EBITDA	3,480	3,601	(3.4)	In-Line
EBITDA Margin (%)	17.7	17.6	12bps	
PAT	2,339	2,395	(2.4)	

Source: DART

Exhibit 2: Change in estimates

(Particulars (Rs Mn))	FY24E			FY25E		
	New	Previous	Chg. (%)	New	Previous	Chg. (%)
Revenue	88,609	89,598	(1.1)	1,02,318	99,479	2.9
EBITDA	16,813	17,506	(4.0)	21,020	21,918	(4.1)
EBITDA Margin(%)	19.0%	19.5%	(2.9)	0.2	0.2	(6.8)
PAT	11,378	11,694	(2.7)	14,046	14,560	(3.5)
EPS(Rs)	83.4	85.7	(2.7)	103.0	106.7	(3.5)

Source: DART

Financial Performance

Profit and Loss Account

(Rs Mn)	FY22A	FY23P	FY24E	FY25E
Revenue	68,022	79,721	88,609	102,318
Total Expense	51,986	66,827	71,796	81,298
COGS	45,530	58,894	62,531	70,751
Employees Cost	2,741	3,183	3,564	3,992
Other expenses	3,715	4,750	5,700	6,555
EBIDTA	16,036	12,894	16,813	21,020
Depreciation	1,777	1,663	2,059	2,726
EBIT	14,259	11,231	14,754	18,295
Interest	340	248	49	49
Other Income	426	476	500	525
Exc. / E.O. items	0	0	0	0
EBT	14,345	11,459	15,205	18,770
Tax	3,678	2,939	3,827	4,724
RPAT	10,666	8,520	11,378	14,046
Minority Interest	0	0	0	0
Profit/Loss share of associates	0	0	0	0
APAT	10,666	8,520	11,378	14,046

Balance Sheet

(Rs Mn)	FY22A	FY23P	FY24E	FY25E
Sources of Funds				
Equity Capital	273	273	273	273
Minority Interest	0	0	0	0
Reserves & Surplus	33,112	40,627	50,982	63,800
Net Worth	33,384	40,900	51,254	64,073
Total Debt	3,225	845	845	845
Net Deferred Tax Liability	1,253	1,565	1,566	1,566
Total Capital Employed	37,862	43,309	53,665	66,483

Applications of Funds

Net Block	20,213	20,862	29,811	37,086
CWIP	1,222	3,008	4,000	4,000
Investments	22	25	25	25
Current Assets, Loans & Advances	22,847	27,391	28,544	34,165
Inventories	5,846	8,931	8,955	10,341
Receivables	11,291	13,095	14,070	16,246
Cash and Bank Balances	418	400	554	2,612
Loans and Advances	4	4	4	4
Other Current Assets	5,289	4,961	4,961	4,961
Less: Current Liabilities & Provisions	6,442	7,977	8,715	8,792
Payables	5,117	6,618	7,355	7,933
Other Current Liabilities	1,325	1,360	1,360	860
<i>sub total</i>				
Net Current Assets	16,405	19,414	19,829	25,373
Total Assets	37,862	43,309	53,665	66,483

E – Estimates

Important Ratios

Particulars	FY22A	FY23P	FY24E	FY25E
(A) Margins (%)				
Gross Profit Margin	33.1	26.1	29.4	30.9
EBIDTA Margin	23.6	16.2	19.0	20.5
EBIT Margin	21.0	14.1	16.7	17.9
Tax rate	25.6	25.6	25.2	25.2
Net Profit Margin	15.7	10.7	12.8	13.7
(B) As Percentage of Net Sales (%)				
COGS	66.9	73.9	70.6	69.1
Employee	4.0	4.0	4.0	3.9
Other	5.5	6.0	6.4	6.4
(C) Measure of Financial Status				
Gross Debt / Equity	0.1	0.0	0.0	0.0
Interest Coverage	41.9	45.3	300.9	373.1
Inventory days	31	41	37	37
Debtors days	61	60	58	58
Average Cost of Debt	7.4	12.2	5.8	5.8
Payable days	27	30	30	28
Working Capital days	88	89	82	91
FA T/O	3.4	3.8	3.0	2.8
(D) Measures of Investment				
AEPS (Rs)	78.2	62.5	83.4	103.0
CEPS (Rs)	91.2	74.7	98.5	123.0
DPS (Rs)	7.0	7.0	7.5	9.0
Dividend Payout (%)	9.0	11.2	9.0	8.7
BVPS (Rs)	244.8	299.9	375.8	469.7
RoANW (%)	37.5	22.9	24.7	24.4
RoACE (%)	32.2	21.6	23.6	23.5
RoAIC (%)	42.2	28.0	30.7	31.3
(E) Valuation Ratios				
CMP (Rs)	1934	1934	1934	1934
P/E	24.7	31.0	23.2	18.8
Mcap (Rs Mn)	263,716	263,716	263,716	263,716
MCap/ Sales	3.9	3.3	3.0	2.6
EV	266,523	264,161	264,007	261,948
EV/Sales	3.9	3.3	3.0	2.6
EV/EBITDA	16.6	20.5	15.7	12.5
P/BV	7.9	6.4	5.1	4.1
Dividend Yield (%)	0.4	0.4	0.4	0.5
(F) Growth Rate (%)				
Revenue	56.0	17.2	11.1	15.5
EBITDA	28.6	(19.6)	30.4	25.0
EBIT	30.3	(21.2)	31.4	24.0
PBT	37.7	(20.1)	32.7	23.4
APAT	37.5	(20.1)	33.5	23.4
EPS	37.5	(20.1)	33.5	23.4

E – Estimates

Cash Flow

Particulars	FY22A	FY23P	FY24E	FY25E
Profit before tax	14,345	11,459	15,205	18,770
Depreciation & w.o.	1,777	1,663	2,059	2,726
Net Interest Exp	340	248	49	49
Direct taxes paid	(3,529)	(2,678)	(3,826)	(4,724)
Change in Working Capital	(4,367)	(3,604)	(261)	(3,485)
Non Cash	0	0	0	0
(A) CF from Operating Activities	8,565	7,088	13,226	13,335
Capex {(Inc.)/ Dec. in Fixed Assets n WIP}	(1,792)	(3,231)	(12,000)	(10,000)
Free Cash Flow	6,774	3,857	1,226	3,335
(Inc.)/ Dec. in Investments	(2,497)	597	0	0
Other	(353)	(798)	0	0
(B) CF from Investing Activities	(4,642)	(3,432)	(12,000)	(10,000)
Issue of Equity/ Preference	0	0	0	0
Inc./ (Dec.) in Debt	(2,769)	(2,462)	0	0
Interest exp net	(340)	(248)	(49)	(49)
Dividend Paid (Incl. Tax)	955	955	1,023	1,228
Other	(1,685)	(1,919)	(2,046)	(2,455)
(C) CF from Financing	(3,840)	(3,674)	(1,072)	(1,277)
Net Change in Cash	84	(18)	154	2,059
Opening Cash balances	334	418	400	554
Closing Cash balances	418	400	554	2,612

E – Estimates

Notes

DART RATING MATRIX

Total Return Expectation (12 Months)

Buy	> 20%
Accumulate	10 to 20%
Reduce	0 to 10%
Sell	< 0%

Rating and Target Price History



DART Team

Purvag Shah	Managing Director	purvag@dolatcapital.com	+9122 4096 9747
-------------	-------------------	-------------------------	-----------------

Amit Khurana, CFA	Head of Equities	amit@dolatcapital.com	+9122 4096 9745
-------------------	------------------	-----------------------	-----------------

CONTACT DETAILS

Equity Sales	Designation	E-mail	Direct Lines
Dinesh Bajaj	VP - Equity Sales	dineshb@dolatcapital.com	+9122 4096 9709
Kapil Yadav	VP - Equity Sales	kapil@dolatcapital.com	+9122 4096 9735
Jubbin Shah	VP - Equity Sales	jubbins@dolatcapital.com	+9122 4096 9779
Girish Raj Sankunny	VP - Equity Sales	girishr@dolatcapital.com	+9122 4096 9625
Pratik Shroff	AVP - Equity Sales	pratiks@dolatcapital.com	+9122 4096 9621
Equity Trading	Designation	E-mail	
P. Sridhar	SVP and Head of Sales Trading	sridhar@dolatcapital.com	+9122 4096 9728
Chandrakant Ware	VP - Sales Trading	chandrakant@dolatcapital.com	+9122 4096 9707
Shirish Thakkar	VP - Head Domestic Derivatives Sales Trading	shirisht@dolatcapital.com	+9122 4096 9702
Kartik Mehta	Asia Head Derivatives	kartikm@dolatcapital.com	+9122 4096 9715
Bhavin Mehta	VP - Derivatives Strategist	bhavinm@dolatcapital.com	+9122 4096 9705

Dolat Capital Market Private Limited.

Naman Midtown, A-1203, 12th Floor, Senapati Bapat Marg, Prabhadevi, Mumbai 400013

Analyst(s) Certification

The research analyst(s), with respect to each issuer and its securities covered by them in this research report, certify that: All of the views expressed in this research report accurately reflect his or her or their personal views about all of the issuers and their securities; and No part of his or her or their compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in this research report.

I. Analyst(s) and Associate (S) holding in the Stock(s): (Nil)**II. Disclaimer:**

This research report has been prepared by Dolat Capital Market Private Limited. to provide information about the company(ies) and sector(s), if any, covered in the report and may be distributed by it and/or its affiliated company(ies) solely for the purpose of information of the select recipient of this report. This report and/or any part thereof, may not be duplicated in any form and/or reproduced or redistributed without the prior written consent of Dolat Capital Market Private Limited. This report has been prepared independent of the companies covered herein. Dolat Capital Market Private Limited. and its affiliated companies are part of a multi-service, integrated investment banking, brokerage and financing group. Dolat Capital Market Private Limited. and/or its affiliated company(ies) might have provided or may provide services in respect of managing offerings of securities, corporate finance, investment banking, mergers & acquisitions, financing or any other advisory services to the company(ies) covered herein. Dolat Capital Market Private Limited. and/or its affiliated company(ies) might have received or may receive compensation from the company(ies) mentioned in this report for rendering any of the above services. Research analysts and sales persons of Dolat Capital Market Private Limited. may provide important inputs to its affiliated company(ies) associated with it. While reasonable care has been taken in the preparation of this report, it does not purport to be a complete description of the securities, markets or developments referred to herein, and Dolat Capital Market Private Limited. does not warrant its accuracy or completeness. Dolat Capital Market Private Limited. may not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. This report is provided for information only and is not an investment advice and must not alone be taken as the basis for an investment decision. The investment discussed or views expressed herein may not be suitable for all investors. The user assumes the entire risk of any use made of this information. The information contained herein may be changed without notice and Dolat Capital Market Private Limited. reserves the right to make modifications and alterations to this statement as they may deem fit from time to time. Dolat Capital Market Private Limited. and its affiliated company(ies), their directors and employees may; (a) from time to time, have a long or short position in, and buy or sell the securities of the company(ies) mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions. This report is neither an offer nor solicitation of an offer to buy and/or sell any securities mentioned herein and/or not an official confirmation of any transaction. This report is not directed or intended for distribution to, or use by any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject Dolat Capital Market Private Limited. and/or its affiliated company(ies) to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to a certain category of investors. Persons in whose possession this report may come, are required to inform themselves of and to observe such restrictions.

For U.S. Entity/ persons only: "This Report is considered independent third-party research and was prepared by Dolat Capital Market Private Limited, with headquarters in India. The distribution of this Research is provided pursuant to the exemption under Rule 15a-6(a) (2) and is only intended for an audience of Major U.S. Institutional Investors (MUSIs) as defined by Rule 15a-6(b)(4). This research is not a product of StoneX Financial Inc. Dolat Capital Market Private Limited has sole control over the contents of this research report. StoneX Financial Inc. does not exercise any control over the contents of, or the views expressed in, any research reports prepared by Dolat Capital Market Private Limited and under Rule 15a-6(a) (3), any U.S. recipient of this research report wishing to affect any transaction to buy or sell securities or related financial instruments based on the information provided in this research report should do so only through StoneX Financial Inc. Please contact Gene Turok at +1 (212) 379-5463 or email gene.turok@stonex.com. Under no circumstances should any U.S. recipient of this research report effect any transaction to buy or sell securities or related financial instruments through the Dolat Capital Market Private Limited."



Dolat Capital Market Private Limited.

Corporate Identity Number: U65990GJ993PTC116741

Member: BSE Limited and National Stock Exchange of India Limited.

SEBI Registration No: BSE - INZ000274132, NSE - INZ000274132, Research: INH000000685

Regd. office: 1401-1409, Dalal Street Commercial, Block 53 (Bldg. No.53E) Zone-5, Road-5E, Gift City, Sector 9, Gandhinagar-382355 Gujarat, India.

Board: +9122 40969700 | Fax: +9122 22651278 | Email: research@dolatcapital.com | www.dolatresearch.com